AnaptysBio Files to Dismiss Tesaro's Claim it Breached Royalties Contract
By Katherine Hamilton
AnaptysBio filed a partial motion to dismiss Tesaro's anticipatory breach of contract claim.
The filing comes after Tesaro in November filed a lawsuit against Anaptys claiming it repudiated a 2014 royalties agreement.
Under the agreement, Tesaro, which is a subsidiary of GSK, was developing Jemperli and San Diego-based Anaptys was eligible to receive royalties for sales of the drug.
Anaptys said it had approached Tesaro before the lawsuit to engage in talks to resolve its claims that Tesaro had breached the royalties agreement.
In response to the lawsuit, Anaptys filed a complaint in a Delaware court requesting a declaration that Tesaro had materially breached the royalties agreement. It filed its motion to dismiss Tesaro's claim on Dec. 30.
The motion was unsealed Thursday and explains why Anaptys never repudiated the agreement.
The court is expected to hear Anaptys' Motion to Dismiss by early March. Tesaro and Anaptys have a trial date scheduled for July 14-17.
The royalty term under the companies' agreement extends at least through expiration of composition of matter coverage on the molecule, which will be in 2035 in the U.S. and 2036 in Europe.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 08, 2026 18:42 ET (23:42 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
5 Stocks to Sell for Tax-Loss Harvesting
Are TIPS ETFs the Best Way to Fight Inflation?
33 Undervalued Stocks to Buy Before the Market Shifts Again
United States